NASDAQ:ATHX - Athersys Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $1.25
  • Forecasted Upside: 53.19 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.82
+0.30 (1.20%)

This chart shows the closing price for ATHX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Athersys Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ATHX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ATHX

Analyst Price Target is $1.25
▲ +53.19% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Athersys in the last 3 months. The average price target is $1.25, with a high forecast of $1.25 and a low forecast of $1.25. The average price target represents a 53.19% upside from the last price of $0.82.

This chart shows the closing price for ATHX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 1 polled investment analysts is to hold stock in Athersys. This rating has held steady since October 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/3/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/1/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/30/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/30/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/29/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/26/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/25/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/19/2021Bank of AmericaDowngradeBuy ➝ Neutral$1.25High
11/10/2020Needham & Company LLCReiterated RatingBuy$5.00High
10/12/2020Dawson JamesReiterated RatingBuyLow
8/11/2020Needham & Company LLCReiterated RatingBuy$5.00High
6/25/2020Bank of AmericaInitiated CoverageBuy$5.00High
5/8/2020Needham & Company LLCLower Price TargetBuy$6.00 ➝ $5.00Low
5/6/2020Dawson JamesReiterated RatingBuy$12.00Low
4/23/2020Smith Barney CitigroupInitiated CoverageOutperform$14.00Low
8/26/2019Dawson JamesInitiated CoverageBuy$11.00High
5/9/2019Maxim GroupReiterated RatingBuy$8.00High
1/23/2019Maxim GroupSet Price TargetBuy$8.00High
8/8/2018Maxim GroupReiterated RatingBuy$6.00High
7/31/2018Maxim GroupReiterated RatingBuy$6.00High
5/11/2018Maxim GroupSet Price TargetBuy$6.00Low
4/23/2018Maxim GroupInitiated CoverageBuy$6.00Medium
3/13/2018Maxim GroupReiterated RatingBuy$6.00High
2/13/2018Maxim GroupSet Price TargetBuy ➝ Buy$12.00 ➝ $6.00Medium
11/16/2017Maxim GroupSet Price TargetBuy$12.00N/A
10/5/2017Maxim GroupSet Price TargetBuy$12.00N/A
9/1/2017Maxim GroupReiterated RatingBuy$12.00High
8/7/2017Maxim GroupSet Price TargetBuy ➝ Buy$9.00 ➝ $12.00High
5/16/2017Maxim GroupSet Price TargetBuy$9.00Medium
5/10/2017Maxim GroupReiterated RatingBuyHigh
3/28/2017William BlairReiterated RatingOutperformHigh
3/20/2017Maxim GroupSet Price TargetBuy$9.00High
3/11/2017Maxim GroupSet Price TargetBuy$9.00Medium
2/7/2017Needham & Company LLCInitiated CoverageBuy$7.00N/A
(Data available from 1/26/2017 forward)

News Sentiment Rating

0.30 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
7/30/2021
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/29/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/28/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/28/2021
  • 0 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
11/27/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
12/27/2021
  • 2 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
1/26/2022

Current Sentiment

  • 2 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Athersys logo
Athersys, Inc. engages in the discovery and development of therapies designed to extend and enhance to quality of human life. It offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas. The company was founded by John J. Harrington and Gil van Bokkelen on October 24, 1995 and is headquartered in Cleveland, OH.
Read More

Today's Range

Now: $0.82
Low: $0.80
High: $0.87

50 Day Range

MA: $0.97
Low: $0.80
High: $1.25

52 Week Range

Now: $0.82
Low: $0.75
High: $3.03

Volume

1,452,713 shs

Average Volume

1,262,170 shs

Market Capitalization

$191.95 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Athersys?

The following Wall Street analysts have issued research reports on Athersys in the last twelve months: Bank of America Co., and Zacks Investment Research.
View the latest analyst ratings for ATHX.

What is the current price target for Athersys?

1 Wall Street analysts have set twelve-month price targets for Athersys in the last year. Their average twelve-month price target is $1.25, suggesting a possible upside of 50.9%. Bank of America Co. has the highest price target set, predicting ATHX will reach $1.25 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $1.25 for Athersys in the next year.
View the latest price targets for ATHX.

What is the current consensus analyst rating for Athersys?

Athersys currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ATHX, but not buy more shares or sell existing shares.
View the latest ratings for ATHX.

How do I contact Athersys' investor relations team?

Athersys' physical mailing address is 3201 CARNEGIE AVENUE, CLEVELAND OH, 44115. The biopharmaceutical company's listed phone number is (216) 431-9900 and its investor relations email address is [email protected] The official website for Athersys is www.athersys.com.